NYSEAMERICAN:ARMP Armata Pharmaceuticals Q4 2025 Earnings Report $5.37 -0.06 (-1.10%) As of 08/28/2026 04:10 PM Eastern ProfileEarnings HistoryForecast Armata Pharmaceuticals EPS ResultsActual EPS-$3.42Consensus EPS -$0.19Beat/MissMissed by -$3.23One Year Ago EPSN/AArmata Pharmaceuticals Revenue ResultsActual Revenue$1.09 millionExpected Revenue$0.74 millionBeat/MissBeat by +$345.00 thousandYoY Revenue GrowthN/AArmata Pharmaceuticals Announcement DetailsQuarterQ4 2025Date3/25/2026TimeBefore Market OpensConference Call DateWednesday, March 25, 2026Conference Call Time8:00AM ETUpcoming EarningsArmata Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Armata Pharmaceuticals Earnings HeadlinesArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate UpdateAugust 13, 2026 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02July 20, 2026 | finanznachrichten.deALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.August 29 at 1:00 AM | Weiss Ratings (Ad)Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02July 20, 2026 | prnewswire.comArmata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is EverythingJuly 17, 2026 | seekingalpha.comArmata Pharmaceuticals Stock Short Interest Report | AMEX:ARMP | BenzingaJuly 13, 2026 | benzinga.comSee More Armata Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email. Email Address About Armata PharmaceuticalsArmata Pharmaceuticals (NYSEAMERICAN:ARMP) is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings. Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens. Its lead program, AP-PA02, has advanced into early-stage clinical evaluation, while additional efforts focus on preclinical development of therapies for diabetic foot infections and anthrax prophylaxis. The company collaborates with U.S. government agencies on biodefense and public health initiatives, underscoring the potential utility of its phage platform in addressing both emerging and established bacterial threats. Founded in 2017 and headquartered in Horsham, Pennsylvania, Armata Pharmaceuticals serves the U.S. market with an eye toward global expansion as clinical data emerge. The company is led by Chairman and Chief Executive Officer George Eliopoulos, whose experience in infectious disease drug development guides Armata’s strategic partnerships and research efforts. Through its innovative biologics approach, Armata aims to deliver safer and more effective treatments for patients facing life-threatening bacterial infections.View Armata Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/24 - 08/28From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens3 Retail Stocks to Watch After a Big Consumer Earnings WeekIREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings3 Financial Stocks Positioned for the Fed’s Next Move After Jackson HoleNutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes ShapeCrowdStrike’s “Mythos Moment” Tests the Bigger AI Security Trade Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
